原发性干燥综合征合并间质性肺疾病临床评估与治疗进展_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

张君 ,  丁晶晶

南京大学医学院附属鼓楼医院呼吸与危重症医学科（江苏南京 210008）;

Corresponding author：

丁晶晶, Email: dingflower@hotmail.com

Keywords：

DOI：

10.7507/1671-6205.202104068

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 张君, 丁晶晶. 原发性干燥综合征合并间质性肺疾病临床评估与治疗进展. Chinese Journal of Respiratory and Critical Care Medicine, 2021, 20(12): 901-904. doi: 10.7507/1671-6205.202104068 Copy

1.	Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. Arthritis Rheumatol, 2017, 69(1): 35-45.
2.	Anaya JM, Rojas-Villarraga A, Mantilla RD, et al. Polyautoimmunity in Sjögren syndrome. Rheum Dis Clin North Am, 2016, 42(3): 457-472.
3.	Bowman SJ, Ibrahim GH, Holmes G, et al. Estimating the prevalence among Caucasian women of primary Sjögren's syndrome in two general practices in Birmingham, UK. Scand J Rheumatol, 2004, 33(1): 39-43.
4.	Qin B, Wang J, Ma N, et al. The association of Tyro3/Axl/Mer signaling with inflammatory response, disease activity in patients with primary Sjögren's syndrome. Joint Bone Spine, 2015, 82(4): 258-263.
5.	Maciel G, Crowson CS, Matteson EL, et al. Reply. Arthritis Care Res (Hoboken), 2018, 70(6): 953-954.
6.	Gupta S, Ferrada MA, Hasni SA. Pulmonary manifestations of primary Sjögren's syndrome: underlying immunological mechanisms, clinical presentation, and management. Front Immunol, 2019, 10: 1327.
7.	Mathai SC, Danoff SK. Management of interstitial lung disease associated with connective tissue disease. BMJ, 2016, 352: h6819.
8.	Takahashi K, Taniguchi H, Ando M, et al. Mean pulmonary arterial pressure as a prognostic indicator in connective tissue disease associated with interstitial lung disease: a retrospective cohort study. BMC Pulm Med, 2016, 16(1): 55.
9.	Flament T, Bigot A, Chaigne B, et al. Pulmonary manifestations of Sjögren's syndrome. Eur Respir Rev, 2016, 25(140): 110-123.
10.	Gao H, Zhang X, He J, et al. Prevalence, risk factors, and prognosis of interstitial lung disease in a large cohort of Chinese primary Sjögren syndrome patients: a case-control study. Medicine (Baltimore), 2018, 97(24): e11003.
11.	Sambataro G, Ferro F, Orlandi M, et al. Clinical, morphological features and prognostic factors associated with interstitial lung disease in primary Sjӧgren's syndrome: a systematic review from the Italian Society of Rheumatology. Autoimmun Rev, 2020, 19(2): 102447.
12.	Yazisiz V, Göçer M, Erbasan F, et al. Survival analysis of patients with Sjögren's syndrome in Turkey: a tertiary hospital-based study. Clin Rheumatol, 2020, 39(1): 233-241.
13.	Ito I, Nagai S, Kitaichi M, et al. Pulmonary manifestations of primary Sjögren's syndrome: a clinical, radiologic, and pathologic study. Am J Respir Crit Care Med, 2005, 171(6): 632-638.
14.	Yazisiz V, Arslan G, Ozbudak IH, et al. Lung involvement in patients with primary Sjögren's syndrome: what are the predictors?. Rheumatol Int, 2010, 30(10): 1317-1324.
15.	Parambil JG, Myers JL, Lindell RM, et al. Interstitial lung disease in primary Sjögren syndrome. Chest, 2006, 130(5): 1489-1495.
16.	Yoo H, Hino T, Han J, et al. Connective tissue disease-related interstitial lung disease (CTD-ILD) and interstitial lung abnormality (ILA): evolving concept of CT findings, pathology and management. Eur J Radiol Open, 2020, 8: 100311.
17.	Dong X, Zhou J, Guo X, et al. A retrospective analysis of distinguishing features of chest HRCT and clinical manifestation in primary Sjögren's syndrome-related interstitial lung disease in a Chinese population. Clin Rheumatol, 2018, 37(11): 2981-2988.
18.	Ramos-Casals M, Brito-Zerón P, Seror R, et al. Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology (Oxford), 2015, 54(12): 2238. Erratum in: Rheumatology (Oxford), 2017, 56(7): 1245.
19.	Zhang T, Yuan F, Xu L, et al. Characteristics of patients with primary Sjögren's syndrome associated interstitial lung disease and relevant features of disease progression. Clin Rheumatol, 2020, 39(5): 1561-1568.
20.	Ludviksdottir D, Valtysdottir ST, Hedenström H, et al. Eight-year follow-up of airway hyperresponsiveness in patients with primary Sjögren's syndrome. Ups J Med Sci, 2017, 122(1): 51-55.
21.	Baqir M, Kluka EM, Aubry MC, et al. Amyloid-associated cystic lung disease in primary Sjögren's syndrome. Respir Med, 2013, 107(4): 616-621.
22.	Shi J, Liu H, Xu W, et al. Pulmonary manifestations of Sjögren's syndrome. Respiration, 2009, 78(4): 377-386.
23.	Kampolis CF, Fragkioudaki S, Mavragani CP, et al. Prevalence and spectrum of symptomatic pulmonary involvement in primary Sjögren's syndrome. Clin Exp Rheumatol, 2018, 36 Suppl 112(3): 94-101.
24.	Lee AS, Scofield RH, Hammitt KM, et al. Consensus Expert Panel (CEP) Members Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren's. Chest, 2021, 159(2): 683-698.
25.	Buvry C, Cassagnes L, Tekath M, et al. Anti-Ro52 antibodies are a risk factor for interstitial lung disease in primary Sjögren syndrome. Respir Med, 2020, 163: 105895.
26.	Okamoto T, Fujii M, Furusawa H, et al. The usefulness of KL-6 and SP-D for the diagnosis and management of chronic hypersensitivity pneumonitis. Respir Med, 2015, 109(12): 1576-1581.
27.	Lee JS, Lee EY, Ha YJ, et al. Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease. Arthritis Res Ther, 2019, 21(1): 58.
28.	Doğru G, Balkarli A, Dogru A. Chronic non-productive cough in patients with primary Sjögren's syndrome. Arch Rheumatol, 2017, 32(4): 303-308.
29.	颜淑敏, 张文, 李梦涛, 等. 原发性干燥综合征573例临床分析. 中华风湿病学杂志, 2010, 14(4): 223-227.
30.	Kobak S, Kalkan S, Kirilmaz B, et al. Pulmonary Arterial Hypertension in Patients with Primary Sjögren's Syndrome. Autoimmune Dis, 2014, 2014: 710401.
31.	Brito-Zerón P, Retamozo S, Kostov B, et al. Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren's syndrome. RMD Open, 2019, 5(2): e001064.
32.	Seror R, Bowman SJ, Brito-Zeron P, et al. EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide. RMD Open, 2015, 1(1): e000022.
33.	Roca F, Dominique S, Schmidt J, et al. Interstitial lung disease in primary Sjögren's syndrome. Autoimmun Rev, 2017, 16(1): 48-54.
34.	Oldham JM, Lee C, Valenzi E, et al. Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease. Respir Med, 2016, 121: 117-122.
35.	Liu Z, Wang J, Lai J, Wang Q, et al. Is it possible to apply the treat-to-target strategy in primary Sjögren's syndrome-associated pulmonary arterial hypertension?. Clin Rheumatol, 2018, 37(11): 2989-2998.
36.	Le Pavec J, Girgis RE, Lechtzin N, et al. Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. Arthritis Rheum, 2011, 63(8): 2456-2464.
37.	Luppi F, Sebastiani M, Silva M, et al. Interstitial lung disease in Sjögren's syndrome: a clinical review. Clin Exp Rheumatol, 2020, 38 Suppl 126(4): 300.
38.	Yeh JJ, Chen HJ, Li TC, et al. Association between Sjogren's syndrome and respiratory failure: put airway, interstitia, and vessels close together: a national cohort study. PLoS One, 2014, 9(10): e110783.
39.	Best AC, Meng J, Lynch AM, et al. Idiopathic pulmonary fibrosis: physiologic tests, quantitative CT indexes, and CT visual scores as predictors of mortality. Radiology, 2008, 246(3): 935-940.
40.	Both T, Dalm VA, van Hagen PM, et al. Reviewing primary Sjögren's syndrome: beyond the dryness - from pathophysiology to diagnosis and treatment. Int J Med Sci, 2017, 14(3): 191-200.

1. Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. Arthritis Rheumatol, 2017, 69(1): 35-45.
2. Anaya JM, Rojas-Villarraga A, Mantilla RD, et al. Polyautoimmunity in Sjögren syndrome. Rheum Dis Clin North Am, 2016, 42(3): 457-472.
3. Bowman SJ, Ibrahim GH, Holmes G, et al. Estimating the prevalence among Caucasian women of primary Sjögren's syndrome in two general practices in Birmingham, UK. Scand J Rheumatol, 2004, 33(1): 39-43.
4. Qin B, Wang J, Ma N, et al. The association of Tyro3/Axl/Mer signaling with inflammatory response, disease activity in patients with primary Sjögren's syndrome. Joint Bone Spine, 2015, 82(4): 258-263.
5. Maciel G, Crowson CS, Matteson EL, et al. Reply. Arthritis Care Res (Hoboken), 2018, 70(6): 953-954.
6. Gupta S, Ferrada MA, Hasni SA. Pulmonary manifestations of primary Sjögren's syndrome: underlying immunological mechanisms, clinical presentation, and management. Front Immunol, 2019, 10: 1327.
7. Mathai SC, Danoff SK. Management of interstitial lung disease associated with connective tissue disease. BMJ, 2016, 352: h6819.
8. Takahashi K, Taniguchi H, Ando M, et al. Mean pulmonary arterial pressure as a prognostic indicator in connective tissue disease associated with interstitial lung disease: a retrospective cohort study. BMC Pulm Med, 2016, 16(1): 55.
9. Flament T, Bigot A, Chaigne B, et al. Pulmonary manifestations of Sjögren's syndrome. Eur Respir Rev, 2016, 25(140): 110-123.
10. Gao H, Zhang X, He J, et al. Prevalence, risk factors, and prognosis of interstitial lung disease in a large cohort of Chinese primary Sjögren syndrome patients: a case-control study. Medicine (Baltimore), 2018, 97(24): e11003.
11. Sambataro G, Ferro F, Orlandi M, et al. Clinical, morphological features and prognostic factors associated with interstitial lung disease in primary Sjӧgren's syndrome: a systematic review from the Italian Society of Rheumatology. Autoimmun Rev, 2020, 19(2): 102447.
12. Yazisiz V, Göçer M, Erbasan F, et al. Survival analysis of patients with Sjögren's syndrome in Turkey: a tertiary hospital-based study. Clin Rheumatol, 2020, 39(1): 233-241.
13. Ito I, Nagai S, Kitaichi M, et al. Pulmonary manifestations of primary Sjögren's syndrome: a clinical, radiologic, and pathologic study. Am J Respir Crit Care Med, 2005, 171(6): 632-638.
14. Yazisiz V, Arslan G, Ozbudak IH, et al. Lung involvement in patients with primary Sjögren's syndrome: what are the predictors?. Rheumatol Int, 2010, 30(10): 1317-1324.
15. Parambil JG, Myers JL, Lindell RM, et al. Interstitial lung disease in primary Sjögren syndrome. Chest, 2006, 130(5): 1489-1495.
16. Yoo H, Hino T, Han J, et al. Connective tissue disease-related interstitial lung disease (CTD-ILD) and interstitial lung abnormality (ILA): evolving concept of CT findings, pathology and management. Eur J Radiol Open, 2020, 8: 100311.
17. Dong X, Zhou J, Guo X, et al. A retrospective analysis of distinguishing features of chest HRCT and clinical manifestation in primary Sjögren's syndrome-related interstitial lung disease in a Chinese population. Clin Rheumatol, 2018, 37(11): 2981-2988.
18. Ramos-Casals M, Brito-Zerón P, Seror R, et al. Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology (Oxford), 2015, 54(12): 2238. Erratum in: Rheumatology (Oxford), 2017, 56(7): 1245.
19. Zhang T, Yuan F, Xu L, et al. Characteristics of patients with primary Sjögren's syndrome associated interstitial lung disease and relevant features of disease progression. Clin Rheumatol, 2020, 39(5): 1561-1568.
20. Ludviksdottir D, Valtysdottir ST, Hedenström H, et al. Eight-year follow-up of airway hyperresponsiveness in patients with primary Sjögren's syndrome. Ups J Med Sci, 2017, 122(1): 51-55.
21. Baqir M, Kluka EM, Aubry MC, et al. Amyloid-associated cystic lung disease in primary Sjögren's syndrome. Respir Med, 2013, 107(4): 616-621.
22. Shi J, Liu H, Xu W, et al. Pulmonary manifestations of Sjögren's syndrome. Respiration, 2009, 78(4): 377-386.
23. Kampolis CF, Fragkioudaki S, Mavragani CP, et al. Prevalence and spectrum of symptomatic pulmonary involvement in primary Sjögren's syndrome. Clin Exp Rheumatol, 2018, 36 Suppl 112(3): 94-101.
24. Lee AS, Scofield RH, Hammitt KM, et al. Consensus Expert Panel (CEP) Members Consensus Guidelines for Evaluation and Management of Pulmonary Disease in Sjögren's. Chest, 2021, 159(2): 683-698.
25. Buvry C, Cassagnes L, Tekath M, et al. Anti-Ro52 antibodies are a risk factor for interstitial lung disease in primary Sjögren syndrome. Respir Med, 2020, 163: 105895.
26. Okamoto T, Fujii M, Furusawa H, et al. The usefulness of KL-6 and SP-D for the diagnosis and management of chronic hypersensitivity pneumonitis. Respir Med, 2015, 109(12): 1576-1581.
27. Lee JS, Lee EY, Ha YJ, et al. Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease. Arthritis Res Ther, 2019, 21(1): 58.
28. Doğru G, Balkarli A, Dogru A. Chronic non-productive cough in patients with primary Sjögren's syndrome. Arch Rheumatol, 2017, 32(4): 303-308.
29. 颜淑敏, 张文, 李梦涛, 等. 原发性干燥综合征573例临床分析. 中华风湿病学杂志, 2010, 14(4): 223-227.
30. Kobak S, Kalkan S, Kirilmaz B, et al. Pulmonary Arterial Hypertension in Patients with Primary Sjögren's Syndrome. Autoimmune Dis, 2014, 2014: 710401.
31. Brito-Zerón P, Retamozo S, Kostov B, et al. Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren's syndrome. RMD Open, 2019, 5(2): e001064.
32. Seror R, Bowman SJ, Brito-Zeron P, et al. EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide. RMD Open, 2015, 1(1): e000022.
33. Roca F, Dominique S, Schmidt J, et al. Interstitial lung disease in primary Sjögren's syndrome. Autoimmun Rev, 2017, 16(1): 48-54.
34. Oldham JM, Lee C, Valenzi E, et al. Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease. Respir Med, 2016, 121: 117-122.
35. Liu Z, Wang J, Lai J, Wang Q, et al. Is it possible to apply the treat-to-target strategy in primary Sjögren's syndrome-associated pulmonary arterial hypertension?. Clin Rheumatol, 2018, 37(11): 2989-2998.
36. Le Pavec J, Girgis RE, Lechtzin N, et al. Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. Arthritis Rheum, 2011, 63(8): 2456-2464.
37. Luppi F, Sebastiani M, Silva M, et al. Interstitial lung disease in Sjögren's syndrome: a clinical review. Clin Exp Rheumatol, 2020, 38 Suppl 126(4): 300.
38. Yeh JJ, Chen HJ, Li TC, et al. Association between Sjogren's syndrome and respiratory failure: put airway, interstitia, and vessels close together: a national cohort study. PLoS One, 2014, 9(10): e110783.
39. Best AC, Meng J, Lynch AM, et al. Idiopathic pulmonary fibrosis: physiologic tests, quantitative CT indexes, and CT visual scores as predictors of mortality. Radiology, 2008, 246(3): 935-940.
40. Both T, Dalm VA, van Hagen PM, et al. Reviewing primary Sjögren's syndrome: beyond the dryness - from pathophysiology to diagnosis and treatment. Int J Med Sci, 2017, 14(3): 191-200.

Previous Article
内皮素-1在急性呼吸窘迫综合征发病机制中的研究进展
Next Article
前列腺素F2α与特发性肺间质纤维化相关性的研究进展

Chinese Journal of Respiratory and Critical Care Medicine

原发性干燥综合征合并间质性肺疾病临床评估与治疗进展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content